NeuroSense Therapeutics - NRSN Company Short-Term Debt

NeuroSense Therapeutics Ltd. (NRSN) - corporate logo

The monopoly potential of ALS therapy will provide NeuroSense Therapeutics (NRSN) with significant pricing power, although current short-term liabilities demonstrate balance sheet pressure due to a high burn rate and trial uncertainty. The value of 0.00 reflects the latest metric value. Cash gap risks are mitigated by transparent grant control and strict regulatory compliance by academic management, which stabilizes the company's financial position.

NeuroSense Therapeutics, Ltd. (NRSN) Company Short-Term Indebtedness: for the period 07/05/2022 - 10/28/2026

NeuroSense Therapeutics Ltd - analytical breakdowns and key metrics (NRSN)

- price and consensus price forecast:
Price Chart NeuroSense Therapeutics, Ltd.|NRSN - Fair Value Consensus
- market capitalization data:
Market Value NeuroSense Therapeutics Ltd.|NRSN - Total Enterprise Value
- book capitalization data:
Net Assets per Single Share NeuroSense Therapeutics|NRSN - Accounting Capitalization|Market Capitalization to Book Value Ratio neurosense-tx.com|NRSN - Company Assets
- debt and liquidity data:
Total Debt to Equity Ratio NeuroSense Therapeutics|NRSN - Long-Term Debt to Capital|Short-Term Debt to Equity NeuroSense Therapeutics, Ltd.|NRSN - Aggregate Debt Obligations|Debt to Book Capitalization Ratio NeuroSense Therapeutics Ltd.|NRSN - Long-Term Debt|Company Short-Term Debt NeuroSense Therapeutics
Fundamental company valuation:neurosense-tx.com, NRSN
Manufactured products of NeuroSense Therapeutics, Ltd.

Developing innovative ALS therapies requires significant capital expenditures, and therefore, analyzing short-term borrowing metrics allows for an assessment of NeuroSense Therapeutics (NRSN) liquidity over a one-year horizon. This metric aggregates all obligations maturing within twelve months, demonstrating the company's ability to fund current research without compromising long-term growth or the brand's financial stability.

Competitor analysis for NeuroSense Therapeutics

Company Short-Term Debt Biogen (BIIB)|NBIX: Company Short-Term Loans and Borrowings|Company Short-Term Debt RGC|AXSM (Axsome Corp) - Short-Term Debt|Company Short-Term Debt ACADIA Pharmaceuticals (ACAD)|Company Short-Term Indebtedness xenon-pharma.com|Viking Therapeutics, Inc. - Company Short-Term Debts|Short-Term Debt Supernus Pharmaceuticals, Inc. SUPN|Company Current Liabilities CPRX (Catalyst Pharmaceuticals Inc)|Denali Corp - Company Short-Term Debts|Company Short-Term Debt Harmony Biosciences (HRMY)|BHVN: Company Short-Term Loans and Borrowings|Company Short-Term Debt AMLX|TRVI (Trevi Therapeutics Inc) - Short-Term Debt|PRAX: Company Short-Term Debt|Short-Term Debt Volume Anavex Life Sciences Corp|CeriBell, Inc. - Company Short-Term Debts|Short-Term Debt PRTA (Prothena Corporation plc)|ALEC - Company Short-Term Debt|Annexon Biosciences - Company Short-Term Indebtedness|Company Short-Term Debt OMER (Omeros Corp.)|NGNE - Short-Term Debt Volume|Company Short-Term Debts ACIU|Short-Term Debt voyagertherapeutics.com|NMRA - Company Current Liabilities|Company Short-Term Loans and Borrowings Scilex Holding (SCLX)|Company Current Liabilities Tevogen Bio Holdings, Inc.|Amount of Current Liabilities alphacognition.com (ACOG)|Company Short-Term Debts Cognition Therapeutics, Inc.|Company Short-Term Loans and Borrowings inhibikase.com IKT|SAVA (Cassava Sciences) - Company Short-Term Debts|ASRT: Short-Term Debt|Company Short-Term Debt coyatherapeutics.com COYA|Vistagen (VTGN) - Company Short-Term Loans and Borrowings|OVID (Ovid Therapeutics Inc) - Company Short-Term Debts|Company Short-Term Debts ABOS|CRVO - Company Short-Term Debt|Current Liabilities alteritytherapeutics.com (ATHE)|CLNN: Company Short-Term Debts|PEPG - Short-Term Debt|Jupiter Neurosciences - Company Current Liabilities|relmada.com (RLMD) - Company Short-Term Debts|ANVS - Company Current Liabilities|Grace Therapeutics (GRCE) - Amount of Current Liabilities|AIFF: Company Short-Term Debts|Short-Term Debt Volume ANEW Medical, Inc.|Company Short-Term Debts RVPH (Reviva Pharmaceuticals)|Company Current Liabilities MTVA (metaviatx.com)|Company Short-Term Debt NRXS|Helius Medical Technologies, Inc. - Short-Term Debt Volume|Passage Bio Corp (PASG) - Company Short-Term Debt|NEUP: Company Short-Term Indebtedness|Company Short-Term Debt Minerva Neurosciences NERV|ATHA (athira.com) - Company Short-Term Loans and Borrowings|ADXN: Company Short-Term Debt|Short-Term Debt Volume ALZN|Company Short-Term Debt Cyclerion Therapeutics CYCN|Company Short-Term Indebtedness PTIX (protagenic.com)|KTTA - Company Short-Term Debt|Company Short-Term Indebtedness Cortigent Inc CRGT|ATXI (Avenue Therapeutics, Inc.) - Company Short-Term Debts|Brainstorm Cell Therapeutics Inc. (BCLI) - Short-Term Debt|CARA: Company Current Liabilities|CHRO (Chromocell) - Company Short-Term Debts|ELYM - Company Short-Term Debt|Company Short-Term Loans and Borrowings ITCI|Longboard Pharmaceuticals, Inc. - Company Short-Term Debt|Short-Term Debt MRNS (Marinus Pharmaceuticals Inc)|NKGN - Company Short-Term Debt|Company Short-Term Indebtedness NeuroBo Pharma NRBO|SAGE (Sage Therapeutics, Inc.) - Company Short-Term Debts|synaptogen.com (SNPX) - Short-Term Debt|TRVN: Company Current Liabilities|VIGL (Vigil Neuroscience, Inc.) - Company Short-Term Debts|WENA - Company Short-Term Debt|Company Short-Term Loans and Borrowings CERE